Revvity, Inc.
RVTY · Price history
Price at last available close
$165.33
+$12.56 (+8.22%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Revvity, Inc.
Primary reporting period: 2025-12-28 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies.
How they make money
Revvity provides health science solutions, technologies, and services that support workflows from discovery to development and diagnosis to cure. The company generates revenue primarily through the sale of specialized instruments, reagents, consumables, and software, as well as through the provision of technical services and clinical laboratory testing.
Products & services
Translational multi-omics technologies, biomarker identification, imaging, screening, detection and diagnosis, and informatics solutions.
Brands & revenue mix
The primary corporate brand under which the company operates its life sciences and diagnostics businesses.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Unnamed third-party contract manufacturers and component suppliers — The company relies on various third-party suppliers for raw materials, components, and contract manufacturing services to support its production workflows.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
26
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
44
Weak
Financial Strength
64
Business Quality / Moat
38
Management
36
Growth Quality
28
Risk / Durability
41
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
21
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
25/100
Building Historical Record
Model Score 25/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •M&A headline · Sep 11, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for RVTY
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can RVTY maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is RVTY's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is RVTY's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify RVTY's current valuation?
Essential Investment Snapshot
Wall Street Score
26
Opportunity Score
21
Market Cap
$18.45B
P/E Ratio
73.1
EPS
$2.10
52-Week High
$166.25
52-Week Low
$81.22
Beta
1.06
Intrinsic Value
$17.85
Analyst Target
$130.00
Shares Outstanding
113.2M
Total Revenue
$2.91B
Total Debt
$3.34B
Reported Dividend Yield
0.19%
Liquidation Value / Share
$63.85
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for RVTY
Detected from reported data — verify before acting.Dividend history reported
The provider reports a dividend yield. Confirm the latest declaration before treating it as a current payment.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Sep 11, 2026
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Zacks Investment ResearchCommunity Sentiment
0 active · 0 total callsNo personal call yet on RVTY.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Comprehensive portfolio covering the full workflow from discovery to diagnosis.
- +High percentage of recurring revenue from consumables, services, and software.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Dependence on third-party suppliers and contract manufacturers.
- −Risks associated with international operations and global supply chain disruptions.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
26
Oct 1, 2026
Change
Unchanged
Current Score
26
Oct 19, 2026
Category Changes
RVTY score was unchanged.
Projected Score
Projected Score
28
Projected Change
+2.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 2.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$165.33
Model Intrinsic Value
$17.85
Difference
+$147.48
+826.2% vs IV
Margin of Safety
-826.2%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.91B | $2.86B | $2.76B | $2.75B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.39B | $1.34B | $1.43B | $1.43B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $1.52B | $1.52B | $1.32B | $1.32B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $215.8M | $215.8M | $196.8M | $216.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $942.6M | $945.3M | $715.3M | $706.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $1.16B | $1.16B | $912.1M | $922.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $767.0M | $765.8M | $840.3M | $713.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $358.8M | $356.6M | $410.5M | $399.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $94.0M | $92.2M | $96.3M | $98.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $260.8M | $268.3M | $316.1M | $183.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $20.8M | $25.8M | $33.1M | $3.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $237.6M | $241.7M | $295.8M | -$118.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $2.10 | $2.08 | $2.41 | $-0.95 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 112M | 113M | 123M | 125M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 112M | 113M | 123M | 125M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$729.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.47
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-1.0%
Cash Change
+3.1%
Margin Change
-0.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels. Pressure indicators included EPS growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 1.3%. EPS was essentially unchanged. Cash increased 3.1%. Total debt declined 1.0%. Net income margin declined by 0.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
A dividend is reported, but detailed payment history is temporarily unavailable or awaiting refresh.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Revvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine
How to Invest in AI Drug Discovery
Revvity to Present at Upcoming Investor Conferences
Rumor Mill · RVTY
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial